The big funding news this fortnight doesn’t come from public or private investors, it comes from taxpayers. As " The Pink Sheet ...

Was FOTF the only one to notice that anti-obesity drug maker Vivus aced its FDA advisory committee review on Feb. 22, one day...

Let’s be honest – we look forward to some FDA advisory committee meetings more than others. Some meetings, such as those convened only becau...

On the eve of FDA’s Antiviral Drugs Advisory Committee reviews of the first protease inhibitors for hepatitis C, the drugs’ sponsors – Merck...

… FedFinancial Federal Credit Union, serving federal employees and their families in the Washington and Baltimore areas since 1935. OK, so ...

Advisory committees are always interesting, but you really have to expect the unexpected when Public Citizen Health Research Group Director ...

The three obesity drugs—Vivus’ Qnexa, Arena’s Lorqess, and Orexigen’s Contrave—pending at FDA haven’t suffered from a lack of buzz in the in...

There was some disharmony at Jazz Pharmaceuticals’ FDA panel review of its drug Rekinla for fibromyalgia. FDA’s Arthritis Drugs Advisory Co...

Roche's CEO Severin Schwan isn't the only pharma CEO facing a highly unappealing economic reality (and not just talking of it) – exe...

Today, FDA released an army of briefing documents ahead of the advisory committee re-review of GlaxoSmithKline's diabetes drug Avandia (...

InterMune’s roller coaster ride with the idiopathic pulmonary fibrosis therapy pirfenidone took a steep dive back down when FDA issued a “co...

That wacky Pulmonary-Allergy Drugs Advisory Committee is at it again! Last month, we noted the remarkable outcome of the review of Intermun...

Two wrongs may not make a right, but when it came to Pulmonary-Allergy Drugs Advisory Committee member Les Hendeles' views on the approv...